Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00060671

Public ClinicalTrials.gov record NCT00060671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.

Study identification

NCT ID
NCT00060671
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
CTI BioPharma
Industry
Enrollment
800 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2005 (Type not available)
Primary completion
Jan 2006 (Actual)
Completion
Jan 2006 (Actual)
Last update posted
Jan 19, 2015

2005 – 2006

United States locations

U.S. sites
38
U.S. states
20
U.S. cities
36
Facility City State ZIP Site status
Arizona Clinical Research Center Tucson Arizona 85712 —
Sutter Health Western Division Cancer Research Group Greenbrae California 94904 —
Kenmar Research Institute Los Angeles California 90057 —
Rocky Moutain Cancer Center Denver Colorado 80218 —
Pasco, Hernando Oncology Associates, P.A. New Port Richey Florida — —
Ocala Oncology Center Ocala Florida 34474 —
Orange Park Cancer Center Orange Park Florida 32073 —
University of Chicago Medical Center Hematology / Oncology Chicago Illinois 60637 —
Illinois Masonic Cancer Center Chicago Illinois 60657 —
Edward Cancer Center Naperville Illinois 60540 —
Hope Center Terre Haute Indiana 47802 —
Commonwealth Hematology/Oncology Danville Kentucky 40422 —
New England Hematology / Oncology Associates Wellesley Massachusetts 02481 —
St. Joseph Oncology Saint Joseph Missouri 64507 —
Christian Hospital St Louis Missouri 63136 —
St. Johns Mercy Medical Center St Louis Missouri 63141 —
Hematology - Oncology Centers of N. Rockies Billings Montana 59101 —
Great Falls Clinic Great Falls Montana 59405 —
East Orange VA Medical Center East Orange New Jersey 07018 —
Hematology Oncology Associates of NJ Paramus New Jersey 07652 —
Summit Medical Group/Overlook Onc Center Summit New Jersey 07901 —
New Mexico Oncology / Hematology Albuquerque New Mexico 87109 —
HemOnCare, P.C. Brooklyn New York 11235 —
Glens Falls Cancer Center Glens Falls New York 12801 —
North Shore - Long Island Jewish Health System New Hyde Park New York 11040 —
New York University New York New York 10016 —
Upstate NY Cancer Research Rochester New York 14623 —
South Shore Hematology-Oncology Associates Rockville Centre New York 11570 —
Clinworks, Inc Charlotte North Carolina — —
Private Practice Canton Ohio 44718 —
Blair Medical Associates Altoona Pennsylvania 16601 —
Lancaster Cancer Center, LTD Lancaster Pennsylvania 17605 —
Santee Hematology Oncology Sumter South Carolina 29150 —
The West Clinic Memphis Tennessee 38120 —
Central Utah Medical Clinic Hematology-Oncology Provo Utah 84604 —
Oncology of Wisconsin Glendale Wisconsin 53212 —
Marshfield Clinic Marshfield Wisconsin 54449 —
Rhinelander Regional Medical Group Onc. Rhinelander Wisconsin 54501 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00060671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2015 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00060671 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →